Characterization of a Mutant Escherichia coli Heat-Labile Toxin, LT(R192G/L211A), as a Safe and Effective Oral Adjuvant
- 2 February 2011
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 18 (4), 546-551
- https://doi.org/10.1128/cvi.00538-10
Abstract
Despite the fact that the adjuvant properties of the heat-labile enterotoxins ofEscherichia coli(LT) andVibrio cholerae(CT) have been known for more than 20 years, there are no available oral vaccines containing these molecules as adjuvants, primarily because they are both very potent enterotoxins. A number of attempts with various degrees of success have been made to reduce or eliminate the enterotoxicity of LT and CT so they can safely be used as oral adjuvants or immunogens. In this report we characterize the structural, enzymatic, enterotoxic, and adjuvant properties of a novel mutant of LT, designated LT(R192G/L211A), or dmLT. dmLT was not sensitive to trypsin activation, had reduced enzymatic activity for induction of cyclic AMP in Caco-2 cells, and exhibited no enterotoxicity in the patent mouse assay. Importantly, dmLT retained the ability to function as an oral adjuvant for a coadministered antigen (tetanus toxoid) and to elicit anti-LT antibodies.In vitroandin vivodata suggest that the reduced enterotoxicity of this molecule compared to native LT or the single mutant, LT(R192G), is a consequence of increased sensitivity to proteolysis and rapid intracellular degradation in mammalian cells. In conclusion, dmLT is a safe and powerful detoxified enterotoxin with the potential to function as a mucosal adjuvant for coadministered antigens and to elicit anti-LT antibodies without undesirable side effects.Keywords
This publication has 38 references indexed in Scilit:
- Development of a Bacillus subtilis -Based Rotavirus VaccineClinical and Vaccine Immunology, 2010
- Options for Inactivation, Adjuvant, and Route of Topical Administration of a Killed, Unencapsulated Pneumococcal Whole-Cell VaccineClinical and Vaccine Immunology, 2010
- Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxinVaccine, 2010
- Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile ToxinPLOS ONE, 2009
- Kinetics of Immune Responses to Influenza Virus-Like Particles and Dose-Dependence of Protection with a Single VaccinationJournal of Virology, 2009
- Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigensVaccine, 2007
- Evaluation of combinatorial vaccines against anthrax and plague in a murine modelVaccine, 2007
- Association of Gamma Interferon and Interleukin-17 Production in Intestinal CD4+T Cells with Protection against Rotavirus Shedding in Mice Intranasally Immunized with VP6 and the Adjuvant LT(R192G)Journal of Virology, 2007
- Protein disulfide isomerase–like proteins play opposing roles during retrotranslocationThe Journal of cell biology, 2006
- Structure of partially‐activated E. coli heat‐labile enterotoxin (LT) at 2.6 Å resolutionFEBS Letters, 1994